Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
Stock Information for Cellectar Biosciences Inc.
Loading
Please wait while we load your information from QuoteMedia.